Mirabegron Add-On Therapy to Tamsulosin in Men with Overactive Bladder: Post Hoc Analyses of Efficacy from the MATCH Stu

  • PDF / 1,013,351 Bytes
  • 19 Pages / 595.276 x 790.866 pts Page_size
  • 82 Downloads / 175 Views

DOWNLOAD

REPORT


ORIGINAL RESEARCH

Mirabegron Add-On Therapy to Tamsulosin in Men with Overactive Bladder: Post Hoc Analyses of Efficacy from the MATCH Study Hidehiro Kakizaki . Kyu-Sung Lee . Daisuke Katou . Osamu Yamamoto . Budiwan Sumarsono . Satoshi Uno . Osamu Yamaguchi

Received: May 13, 2020 / Accepted: September 28, 2020 Ó The Author(s) 2020

ABSTRACT Introduction: MATCH was a randomized, double-blind, placebo-controlled study enrolling Japanese and Korean men aged C 40 years who still had overactive bladder (OAB) symptoms while receiving tamsulosin. After a 4-week single-blind screening period in which patients received placebo and tamsulosin, patients were randomized to mirabegron 50 mg ? tamsulosin or placebo ? tamsulosin for 12 weeks (n = 568). This post hoc analysis investigated the

H. Kakizaki Asahikawa Medical University, Asahikawa, Japan K.-S. Lee Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea D. Katou (&)  O. Yamamoto  S. Uno Astellas Pharma Inc., Tokyo, Japan e-mail: [email protected] B. Sumarsono Astellas Pharma, Singapore, Singapore O. Yamaguchi Division of Bioengineering and LUTD Research, Nihon University School of Engineering, Koriyama, Japan

proportion of treatment responders for each treatment group and for subgroups stratified by age based on voiding diaries and patient-reported outcomes (PROs). Methods: Responders were defined as those achieving normalization or clinically meaningful improvements in efficacy, or clinically important differences in PROs [C 10-point improvement in OAB questionnaire (OAB-q) symptom bother or total health-related quality of life (HRQoL) subscales at end of treatment (EoT; minimally important difference [MID]) or OAB symptom score (OABSS) total score decreased by C 3 points at EoT [minimally clinically important change (MCIC)]]. Results: At EoT, micturition frequency normalization was achieved by 30.7% of tamsulosin ? mirabegron patients and 18.6% of tamsulosin ? placebo patients. Normalization of urgency and incontinence was 19.1% and

Adv Ther

60.7% for tamsulosin ? mirabegron and 18.2% and 60.0% for tamsulosin ? placebo. Normalization of OAB symptoms based on OABSS was 17.1% for tamsulosin ? mirabegron and 14.5% for tamsulosin ? placebo. Higher proportions of patients in the mirabegron add-on group versus the placebo group reported clinically meaningful improvements in micturitions, urgency, and incontinence and in MCIC for OABSS and MID for the OAB-q subscales. Double- and triple-responder findings were as predicted by the results of singleresponder analyses. These results were mirrored in the age groups using cut-offs of 65 and 75 years. Conclusion: Mirabegron therapy added on to tamsulosin resulted in a higher frequency of responders in terms of normalization (e.g., micturition frequency normalization), clinically meaningful improvements in efficacy (e.g., C 50% decrease in urgency), and minimally important changes in PROs (e.g., MCIC in OABSS). Trial Registration: ClinicalTrials.gov identifier, NCT02656173.

Mirabe